The FDA-approved treatment is placed at the base of the patient’s esophagus during laparoscopic surgery to support a weak lower esophageal sphincter. The LINX closes the valve to prevent stomach acid from entering the esophagus. Of the 1,500 patients who received the treatment on a trial basis, LINX has shown to control acid reflux and have a low-rate of reoperation over the past three years, according to the report.
More Articles on Surgery Centers:
ASC QI Projects: Best Ideas for Biggest Impact
Cost Cutting at ASCs: Best Initatives From ASC Leaders
How Narrow Networks Impact ASCs: Is Joining the Best Option?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
